Today: 7 February 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai (which is majority-owned by Roche reuters.com) to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited a buying frenzy ts2.tech. By mid-day Friday, RANI was up ~180% on the session ts2.tech, markedly outpacing the broader market’s modest gains (the S&P 500 and Nasdaq Composite were each up only ~0.5% that day investing.com). Deal Details: Under the Chugai
18 October 2025
·
Beyond Meat Stock Implodes: 60% Crash After Shocking Debt-For-Equity Swap

Beyond Meat Stock Implodes: 60% Crash After Shocking Debt-For-Equity Swap

Debt Restructure Sparks Stock Crash Beyond Meat’s brand remains visible to consumers, but behind the scenes its finances are in crisis. In mid-October 2025 the company announced an early settlement of its convertible debt exchange offer, triggering a historic market reaction. As Reuters reports, BYND shareholders are “agonizing” after the company offered existing bondholders new debt and stock in place of their $1.1 billion 2027 notes reuters.com globenewswire.com. With ~96.9% of noteholders participating, Beyond Meat will issue about $196.2 M in new 7.0% convertible notes (due 2030) plus a $12.5 M tender premium – roughly $208.7 M total – and 316.15 million new shares
18 October 2025
Liberty Energy (LBRT) Stock Surges 28% After Q3 Earnings – What’s Next?

Liberty Energy (LBRT) Stock Surges 28% After Q3 Earnings – What’s Next?

Stock Surges on Q3 Results Liberty Energy’s logo (shown above) has been in the spotlight as the stock rallied on the latest earnings. On October 17, one day after Liberty’s Q3 report, the stock soared ~28% intraday, closing at $15.32 (vs. $11.94 the previous day) reuters.com ts2.tech. That move (adding about $3.4 per share of value overnight) came even though broader markets were relatively calm. Traders piled in on the “better-than-feared” outcome. By contrast, LBRT’s shares had been drifting lower for months; at one point earlier in Oct they were down over 40% on the year ts2.tech. Why the sudden
18 October 2025
··
Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

In summary, Gilead’s share price has rallied on a wave of HIV-related breakthroughs, pipeline achievements, and upbeat guidance. With third-quarter results due Oct. 30, investors will be watching for sustained growth. For now, analysts remain generally optimistic: the consensus rating is “Buy” (with average target ~$125) based on Gilead’s diversified portfolio and innovation investing.com ts2.tech. As management shifts into high gear on oncology and global health programs (e.g. a PEPFAR-backed plan to deliver Yeztugo overseas), the long-term outlook is that Gilead’s multiple drivers will more than offset sector risks. Sources: Recent financial filings and earnings commentary gilead.com stockanalysis.com; industry news
18 October 2025
Gold Mania 2025: Record Rally Shatters Records – $5,000 in Sight?

Gold Mania 2025: Record Rally Shatters Records – $5,000 in Sight?

Gold prices have soared this October, breaching $4,300/oz for the first time ever and up over 60% year-to-date reuters.com reuters.com. The safe-haven rally is driven by Fed rate-cut expectations, US political uncertainty and global tensions economictimes.indiatimes.com reuters.com. Analysts note no clear end to the rally: Metals Focus’s Matthew Piggott targets ~$5,000/oz absent a “major shift” ts2.tech, and HSBC now sees gold averaging near $5,000 by 2026 reuters.com reuters.com. In Asia, Diwali/Dhanteras festival buying has pushed Indian premiums to decade highs reuters.com, with domestic prices at ~₹1,31,700 per 10g reuters.com. Bullion flows are “insatiable” – record ETF inflows (~$64bn YTD) and
18 October 2025
·
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Menopause Launch Sparks Surge in HIMS Stock Hims & Hers’ expansion into menopause care was greeted with enthusiasm in the market. On October 15, the San Francisco–based telehealth provider announced it is now offering affordable treatment plans for women in perimenopause and menopause via its Hers platform businesswire.com businesswire.com. The move adds a new specialty to Hers, which already serves over 500,000 women subscribers businesswire.com. By connecting patients with providers trained in menopause care, Hims & Hers aims to fill a long-neglected gap in women’s health. “Women have been navigating an outdated healthcare system that wasn’t designed for them for
17 October 2025
Regions Financial Stock Surges on Strong Q3 Profit; Analysts Upbeat on Outlook

Regions Financial Stock Surges on Strong Q3 Profit; Analysts Upbeat on Outlook

Stock Price and Recent Performance Regions Financial’s stock has seen whipsaw volatility in recent days. Last week’s renewed banking sector fears – sparked by a $50 million fraud-related loan loss at Zions Bancorp and other credit worries – hit regional bank stocks hard, sending the KBW Regional Banking Index down over 6% on Oct. 16 ts2.tech. Regions was caught in that downdraft, with RF shares plunging about 5–6% on Thursday (Oct. 16) to close around $23.33 marketbeat.com, a multi-month low. However, sentiment swiftly reversed after Regions reported strong Q3 results before the market opened on Oct. 17. The stock bounced roughly 2% higher in
17 October 2025
·
VirnetX Stock Soars 71% on Major Government Contract – What’s Next for VHC?

VirnetX Stock Soars 71% on Major Government Contract – What’s Next for VHC?

Major Government Contract Sends VHC Soaring VirnetX shocked the market with an eye-popping rally on October 17, 2025, after unveiling a significant government deal. The Nevada-based cybersecurity firm announced it won a General Services Administration (GSA) Multiple Award Schedule contract late Thursday, and by Friday’s open the stock exploded upward stocktwits.com. Shares opened 71% higher and briefly touched a level not seen in over two years stocktwits.com. The exuberance was directly tied to the GSA news, which investors interpreted as a game-changer for VirnetX’s federal business prospects. The GSA Multiple Award Schedule is essentially a pre-approved vendor list and purchasing
17 October 2025
·
Harrison Global Stock Surges on Bitcoin Treasury Strategy and Expansion Plans

Harrison Global Stock Surges on Bitcoin Treasury Strategy and Expansion Plans

Harrison Global Holdings (NASDAQ: BLMZ) shares jumped about 11–12% on Oct 17, 2025, trading near $0.22 google.com (up from around $0.19 the previous session investing.com). A pre-market report noted a ~19% spike to $0.23 after hours gurufocus.com. – The company announced on Oct 17 a binding term sheet with White Lion Capital to execute a Bitcoin Purchase Agreement, formally launching a “Bitcoin Treasury Strategy” marketwirenews.com. Harrison says this is meant to diversify its cash reserves and hedge inflation marketwirenews.com. – Investor Sentiment: Technical indicators are mixed. GuruFocus notes BLMZ’s RSI is around 47 (neutral) and its annualized volatility is very
17 October 2025
·
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Stock Price Surge & Recent Performance Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare FDA Commissioner’s National Priority Voucher (CNPV) for cytisinicline’s vaping cessation indication investing.com. This rally propelled the shares to multi-month highs in the mid-$3 range. Earlier in the week, ACHV had already begun gaining momentum – on Oct. 15 the stock broke above its 200-day moving average (~$2.81) and hit $3.19 marketbeat.com, a bullish technical signal. As of Thursday’s close (Oct.
17 October 2025
··
Huntington Bancshares’ Profit Surge Defies Banking Jitters – HBAN Stock Eyes Rebound

Huntington Bancshares’ Profit Surge Defies Banking Jitters – HBAN Stock Eyes Rebound

HBAN Stock Bounces After Regional Bank Rout HBAN shares are attempting a comeback after a volatile week. On October 16, Huntington’s stock slid 5.2% to $15.37 markets.financialcontent.com amid a broader rout in regional bank stocks. Credit jitters hit the sector after a “cockroach” of bad loan news – one mid-sized lender disclosed a fraud-linked loss and another flagged sour commercial loans ts2.tech ts2.tech. The KBW Regional Bank Index plunged ~6.5% that day ts2.tech, dragging down even healthy banks like Huntington. However, Huntington’s strong earnings report on Friday, Oct. 17 helped ease those fears. The bank’s better-than-expected results and upbeat guidance
17 October 2025
Ally Financial Stock Soars on Profit Surge – Analysts Bullish on What’s Next

Ally Financial Stock Soars on Profit Surge – Analysts Bullish on What’s Next

Strong Q3 Earnings Fuel Rally Ally Financial delivered an upside surprise in Q3 2025, powering a relief rally in its stock. The Detroit-based digital bank – a major auto lender and online banking provider – reported third-quarter earnings on October 17 that handily beat expectations. Net income more than doubled year-over-year, rising to $371 million (GAAP EPS $1.18) versus $171 million (EPS $0.55) in Q3 2024 nasdaq.com. On an adjusted basis, earnings were $1.15 per share, about 14% above analyst consensus of ~$1.01 chartmill.com. Revenue came in at $2.17 billion, up ~3% from a year ago and slightly ahead of
17 October 2025
1 … 123 124 125 126 127 … 233

Stock Market Today

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

7 February 2026
Kenvue shares closed Friday at $18.13, up 0.33%, with about 63.5 million shares traded. The Kimberly-Clark offer values Kenvue at roughly $18.76 per share, leaving a deal spread of about 3%. Both companies’ shareholders approved the merger, which is expected to close in the second half of 2026 pending regulatory approvals. Kenvue’s dividend record date is Feb. 11, with earnings due Feb. 17.
IREN stock heads into Monday after 5% rebound as Microsoft AI financing stays in focus

IREN stock heads into Monday after 5% rebound as Microsoft AI financing stays in focus

7 February 2026
IREN shares closed up 5.1% at $41.83 Friday after reporting a $155.4 million quarterly loss and $184.7 million in revenue. The company announced $3.6 billion in GPU financing for its Microsoft contract, with $2.8 billion in cash as of Jan. 31. Bitcoin mining revenue fell, while AI cloud services rose. Traders await bitcoin’s weekend move and Monday’s market reaction.
Cadence Bank stock is stuck at $42.11 after Huntington deal — what CADE holders watch next week

Cadence Bank stock is stuck at $42.11 after Huntington deal — what CADE holders watch next week

7 February 2026
Cadence Bank shares have been delisted following Huntington Bancshares’ takeover, with each Cadence share converted into 2.475 Huntington shares. Huntington closed Friday at $19.27 and named Senthil Kumar as chief risk officer ahead of new regulatory requirements. The merger leaves Cadence as a brand under Huntington, with customer account conversions planned for mid-2026. Huntington executives will address investors at a UBS conference on Tuesday.
Go toTop